Skip to main content

Table 2 Baseline characteristics and 5-year outcome according to baseline and 5-year anti-CCP status

From: Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis

 

Anti-CCP negative at baseline

Anti-CCP positive at baseline

5-year anti-CCP status

Anti-CCP negative

(n= 436, 98%)

CCP-/-

Anti-CCP positive

(n= 9, 2%)

CCP-/+

P value

Anti-CCP negative

(n= 9, 4.6%)

CCP+/-

Anti-CCP positive

(n= 186, 95.4%)

CCP+/+

P value

Baseline characteristic

      

Age (n = 640)

51.9 (40.7, 63.1)

47.1 (42.8, 57.1)

0.39

53.4 (50.1, 58.5)

56.1 (48.1, 65.0)

0.46

Female (n = 640)

293 (67%)

7 (78%)

0.72

5 (56%)

114 (61%)

0.74

Symptom duration (n = 596)

4.9 (2.1, 10.4)

3.6 (2.5, 10.1)

0.77

4.8 (3.1, 6.1)

5.3 (2.9, 10.9)

0.82

RF +ve (n = 640)

43 (9.8%)

3 (33%)

0.06

6 (67%)

130 (70%)

1.0

Anti-CCP titer (n = 596)

0.8 (0.5, 1.4)

1.5 (1.4, 3.8)

0.0004

16.2 (13.0, 41.6)

66.8 (32, 101)

0.005

SE - 1 or 2 copies (n = 593)

213 (53%)

7 (100%)

0.017

7 (88%)

138 (78%)

1.0

HAQ (n = 639)

0.6 (0.3, 1.1)

1.1 (0.6, 1.3)

0.13

0.8 (0.4, 1.5)

0.9 (0.4, 1.6)

0.88

CRP (n = 591)

3 (0, 11)

4 (1, 14)

0.73

10 (6, 16)

11 (4, 26)

0.83

Swollen joints (n = 640)

6 (2, 12)

11 (5, 13)

0.12

5 (2, 10)

8 (4, 17)

0.22

Tender joints (n = 640)

7 (2, 16)

15 (6, 24)

0.11

7 (5, 8)

9 (4, 16)

0.24

DAS28 (n = 591)

3.7 (2.7, 4.8)

5.1 (3.2, 5.5)

0.22

4.0 (3.2, 4.5)

4.5 (3.5, 5.4)

0.30

Current smoker (n = 640)

102 (23%)

2 (22%)

1.0

0 (0)

56 (30%)

0.06

Fulfils ACR criteria (n = 640)

168 (39%)

4 (44%)

0.74

6 (67%)

135 (73%)

0.71

Outcome year 5

      

Erosions (n = 523)

95 (27%)

6 (85%)

0.002

6 (75%)

125 (80%)

0.66

Larsen score (n = 521)

2 (0, 10)

35 (19, 71)

0.001

28 (5, 44)

28 (11, 43)

0.80

HAQ (n = 639)

0.6 (0, 1.4)

1.6 (0.1, 2.1)

0.24

1.1 (0.4, 1.8)

1.1 (0.5, 2)

0.40

Swollen joints (n = 475)

1 (0, 3)

2 (1, 5)

0.07

1 (0, 2)

3 (0, 8)

0.04

Tender joints (n = 475)

1 (0, 6)

3 (0, 11)

0.67

2 (0, 4)

3(0, 11)

0.20

DAS28 (n = 463)

2.2 (1.4, 3.1)

2.9 (1.6, 4.2)

0.25

1.7 (1.2, 3.4)

3.3 (2.4, 4.4)

0.03

DMARD received (n = 639)

124 (29%)

8 (89%)

< 0.0001

7 (78%)

162 (87%)

0.34

Fulfils ACR criteria (n = 639)

268 (62%)

8 (89%)

0.16

8 (89%)

179 (96%)

0.32

  1. Continuous variables expressed as median (interquartile range) and compared by using the Mann-Whitney U test. Categoric variables expressed as number (percentage) and compared by using the Fisher Exact test. ACR, American College of Rheumatology criteria for rheumatoid arthritis; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug;
  2. HAQ, Health Assessment Questionnaire; RF, rheumatoid factor.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us